{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066396","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.867953+00:00","generated_at":"2026-05-22T05:20:51.419907+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dyne Q1 net loss $115.4M ($1.05/sh); advances DM1 & DMD toward 2026-2027 approvals","bullets":["Cash $677.5M; expects funding operations into H2 2026.","R&D expenses $106.4M (Q1 2025) vs $44.5M (Q1 2024); net loss widened.","ACHIEVE Registrational Expansion Cohort for DYNE-101 (DM1) initiated; up to 48 patients; data H1 2026.","DELIVER Registrational Expansion Cohort for DYNE-251 (DMD) fully enrolled (32 patients); data late 2025.","New CFO (Erick Lucera), CBO (Vikram Ranade), CSO (Ranjan Batra); Oxana Beskrovnaya named CIO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066396","json":"https://secwatch.observer/filing/0000950170-25-066396.json","markdown":"https://secwatch.observer/filing/0000950170-25-066396.md","text":"https://secwatch.observer/filing/0000950170-25-066396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025066396/0000950170-25-066396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025066396/dyn-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:20:51.419907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}